Blauvelt, Andrew, Oregon Medical Research Center, Portland, OR, USA, United States
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Atopic Dermatitis
Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 8 No. 2 (2024): March 2024 Issue - Posters from 2024 WCH and WCM Conferences: Psoriasis
Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 4 (2022): July 2022 Issue - Poster Presentations from FC PANP 22 Dermatology Conference®: Psoriasis
Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Psoriasis
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Miscellaneous
Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®) - Atopic Dermatitis
Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Atopic Dermatitis
Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Atopic Dermatitis
Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Atopic Dermatitis
Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Mean Percentage Improvement in Psoriasis Area and Severity Index (PASI) Response and Absolute PASI Through 5 Years of Continuous Treatment With Guselkumab (GUS) in VOYAGE 1
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 8 No. 1 (2024): January 2024 Issue - Atopic Dermatitis
Improvement of the Head and Neck Regions with Continuous Tralokinumab treatment for Up to 4 years in Adults with Moderate-to-Severe Atopic Dermatitis
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23 - Posters from FC PANP 23 Dermatology Conference®: Psoriasis
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Atopic Dermatitis
Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Atopic Dermatitis
3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 8 No. 2 (2024): March 2024 Issue - Posters from 2024 WCH and WCM Conferences: Psoriasis
Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Posters from 2023 WCH Dermatology Conference: Psoriasis
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®) - Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
Poster PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 8 No. 2 (2024): March 2024 Issue - Posters from 2024 WCH and WCM Conferences: Psoriasis
Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
PDF
-
SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Abstract
PDF